Hepion Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Hepion Pharmaceuticals's earnings have been declining at an average annual rate of -30%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually.
Key information
-30.0%
Earnings growth rate
111.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | n/a |
| Return on equity | -130.6% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Hepion Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -52 | 11 | 39 |
| 31 Dec 22 | 0 | -45 | 10 | 33 |
| 30 Sep 22 | 0 | -45 | 12 | 33 |
| 30 Jun 22 | 0 | -46 | 12 | 33 |
| 31 Mar 22 | 0 | -34 | 10 | 21 |
| 31 Dec 21 | 0 | -33 | 10 | 20 |
| 30 Sep 21 | 0 | -28 | 10 | 16 |
| 30 Jun 21 | 0 | -25 | 10 | 14 |
| 31 Mar 21 | 0 | -22 | 9 | 13 |
| 31 Dec 20 | 0 | -20 | 8 | 12 |
| 30 Sep 20 | 0 | -18 | 7 | 10 |
| 30 Jun 20 | 0 | -13 | 6 | 7 |
| 31 Mar 20 | 0 | -15 | 5 | 5 |
| 31 Dec 19 | 0 | -12 | 5 | 3 |
| 30 Sep 19 | 0 | -12 | 5 | 3 |
| 30 Jun 19 | 0 | -20 | 6 | 4 |
| 31 Mar 19 | 0 | -17 | 7 | 6 |
| 31 Dec 18 | 0 | -18 | 7 | 8 |
| 30 Sep 18 | 0 | -17 | 7 | 10 |
| 30 Jun 18 | 0 | -14 | 7 | 12 |
| 31 Mar 18 | 0 | -8 | 7 | 13 |
| 31 Dec 17 | 0 | -13 | 7 | 13 |
| 30 Sep 17 | 0 | -16 | 7 | 14 |
| 30 Jun 17 | 0 | -15 | 7 | 14 |
| 31 Mar 17 | 0 | -22 | 7 | 14 |
| 31 Dec 16 | 0 | -18 | 6 | 15 |
| 30 Sep 16 | 0 | -17 | 6 | 14 |
| 30 Jun 16 | 0 | -17 | 6 | 15 |
| 31 Mar 16 | 0 | -17 | 6 | 15 |
| 31 Dec 15 | 0 | -21 | 6 | 14 |
| 30 Sep 15 | 0 | -26 | 6 | 12 |
| 30 Jun 15 | 0 | -22 | 6 | 8 |
| 31 Mar 15 | 0 | -12 | 4 | 5 |
| 31 Dec 14 | 0 | -14 | 3 | 2 |
| 30 Sep 14 | 0 | -7 | 2 | 1 |
| 30 Jun 14 | 0 | -5 | 1 | 0 |
Quality Earnings: 336 is currently unprofitable.
Growing Profit Margin: 336 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 336 is unprofitable, and losses have increased over the past 5 years at a rate of 30% per year.
Accelerating Growth: Unable to compare 336's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 336 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 336 has a negative Return on Equity (-130.62%), as it is currently unprofitable.